• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

833.56 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
August 25, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
August 24, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
August 21, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
REGN Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regeneron Pharmaceuticals Securities Lawsuit - Contact Levi & Korsinsky
August 20, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Deadline
August 20, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Regeneron Announces Investor Conference Presentations
August 19, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP)
August 19, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
August 18, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 17, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
August 15, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 13, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
August 12, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
August 11, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 10, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 07, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
REGN Stock Drop: If You Lost Money Investing in Regeneron Pharmaceuticals, Inc. Contact Robbins LLP for Information About Leading the Class Action Lawsuit
August 05, 2026
From Robbins LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
August 04, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
August 04, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 04, 2026
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Regeneron Awards $150,000 to Winners of the 2026 Regeneron Prize for Creative Innovation
July 31, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Reports Second Quarter 2026 Financial and Operating Results
July 30, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
July 29, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
July 28, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
July 24, 2026
From Schall Law
Via GlobeNewswire
News headline image
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
July 23, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN
July 23, 2026
San Diego, California--(Newsfile Corp. - July 23, 2026) - Robbins LLP reminds stockholders that a class action was filed on... 
Via Newsfile
Topics Earnings
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
July 23, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
July 23, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
July 22, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
July 21, 2026
From Bleichmar Fonti & Auld LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap